This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Brian Goodman, PhD
Co-Founder and Chief Operating Officer at Aktis Oncology


Brian Goodman is a Co-Founder and Head of Corporate Development and Operations at Aktis Oncology. He is also a Principal at MPM Capital, serves as a member of the Board of Directors at Orna Therapeutics, and is a Board Observer for Triplet Therapeutics. Prior to his time at Aktis, Brian was the Vice President, Head of Business Development at Orna Therapeutics; the Co-Founder and Head of Innovation and Technology at Evelo Biosciences; as well as a Senior Associate with Flagship Pioneering where he worked with the entrepreneurial division to build and launch new biotech ventures. While Brian’s most recent experience has centered on creating, building, and financing early-stage biotech companies, he is a biochemist by training and has worked across a diverse span of science, drug discovery and development including the microbiome, extracellular vesicles, nonviral delivery, RNA medicines, and radiopharmaceuticals. Brian holds a PhD in Biological Chemistry and Molecular Pharmacology from Harvard Medical School.

Agenda Sessions

  • The Targeted Radiotherapy Renaissance: Why Investors and Drug Developers See Category Potential for Targeted Radiotherapy